



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

**Figdor et al.**

**Serial No.: 10/808,681**

**Filed: March 25, 2004**

**For: MELANOMA ASSOCIATED  
PEPTIDE ANALOGUES AND VACCINES  
AGAINST MELANOMA**

**Confirmation No.: 8137**

**Examiner: To be assigned**


**Group Art Unit: To be assigned**

**Attorney Docket No.: 2578-4230.1US**

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 21, 2004  
Date

  
Signature

Betty Vowles  
Name (Type/Print)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#US - 5,731,172	03-24-1998	Saito et al.
#US - 6,204,052	03-20-2001	Bout et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#2,053,187	04-11-1993	Massie et al.
#2 707 664	01-20-1995	Perricaudet
#WO 98/02538	01-22-1998	Figdor et al.

Other Documents

#BOCCHIA et al., Abstract, Specific binding of leukemia oncogene fusion protein peptides to H class I molecules, Blood, May 15, 1995, pp. 2680-84, Vol. 85, No. 10.

#BRISTOW et al., Abstract, Solid-phase antigen binding by purified immunoproteins from antigen-specific monoclonal T cell hybridomas, Mol. Immunol. July 1989, pp. 611-24, Vol. 26, No. 7.

#GETHER et al., Abstract, Stable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells, FEBS Letters, January 27, 1992, pp. 241-44, Vol. 296, No. 3.

#HARTWELL et al., Integrating Genetic Approaches into the Discovery of Anticancer Drugs, Science, November 7, 1997, pp. 1064-68, Vol. 278.

#LILLY et al., Abstract, Effects of chronic airway inflammation on the activity and enzyme inactivation of neuropeptides in guinea pig lungs, J. Clin. Invest, June 1994, pp. 2667-74, Vol. 93, No. 6.

#PHAN et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, PNAS, July 8, 2003, pp. 8372-77, Vol. 100, No. 14.

#ROSENBERG et al., Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine, 1999, The Journal of Immunology, pp. 1690-95.

#ROSENBERG, Steven A., Progress in human tumour immunology and immunotherapy, Nature, May 17, 2001, pp. 380-84, Vol. 411.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:


Serial No.: 09/214,836

Filed: 10/4/1999

For: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,



Bretton L. Crockett  
Registration No. 44,632  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: April 20, 2004  
BLC/bv

Enclosures: Form PTO/SB/08

Document in ProLaw

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	10/808,681
Filing Date	March 25, 2004
First Named Inventor	Figdor et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2578-4230 IUS

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		#BOCCHIA et al., Abstract, Specific binding of leukemia oncogene fusion protein peptides to H class I molecules, Blood, May 15, 1995, pp. 2680-84, Vol. 85; No. 10.	
		#BRISTOW et al., Abstract, Solid-phase antigen binding by purified immunoproteins from antigen-specific monoclonal T cell hybridomas, Mol. Immunol. July 1989, pp. 611-24, Vol. 26, No. 7.	
		#GETHER et al., Abstract, Stable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells, FEBS Letters, January 27, 1992, pp. 241-44, Vol. 296, No. 3.	
		#HARTWELL et al., Integrating Genetic Approaches into the Discovery of Anticancer Drugs, Science, November 7, 1997, pp. 1064-68, Vol. 278.	
		#LILLY et al., Abstract, Effects of chronic airway inflammation on the activity and enzyme inactivation of neuropeptides in guinea pig lungs, J. Clin. Invest. June 1994, pp. 2667-74, Vol. 93, No. 6.	
		#PHAN et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, PNAS, July 8, 2003, pp. 8372-77, Vol. 100, No. 14.	
		#ROSENBERG et al., Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine, 1999, The Journal of Immunology, pp. 1690-95.	
		#ROSENBERG, Steven A., Progress in human tumour immunology and immunotherapy, Nature, May 17, 2001, pp. 380-84, Vol. 411.	

Examiner  
SignatureDate  
Considered

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/214,836

Filed: 10/4/1999

For: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.